Navigation Links
Cephalon Conference Call Invitation
Date:5/5/2008

Tuesday, May 6, 2008, 5:30 p.m. U.S. EDT

FRAZER, Pa., May 5 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) today announced plans to host an investor conference call at 5:30 p.m. EDT on May 6, 2008 to discuss the U.S. Food and Drug Administration advisory committee panel meeting held that day. The advisory committee panel is considering the company's supplemental New Drug Application for FENTORA(R) (fentanyl buccal tablet) [C-II] for the management of breakthrough pain in opioid-tolerant patients with chronic pain.

May 6, 2008 Schedule

5:20 p.m. EDT To participate in the conference call, dial 913-312-0407

and refer to Conference Code Number 2046179

5:30 p.m. EDT Conference call begins promptly.

Simultaneous Webcast

Investors can listen to the call live by logging on to the company's website at http://www.cephalon.com and clicking on "Investor Information" then "Webcast." Please click on the link and follow the prompts for registration and access.

If you are unable to listen to the live broadcast, an audio or webcast replay of the call will be available approximately two hours after the event until Midnight EDT, May 20, 2008. To listen to the audio replay, dial 719- 457-0820 and use the Conference Code Number 2046179.

Additional information presented on the conference call may be made available on the Investor Information page of the company's website.


'/>"/>
SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related medicine news :

1. Cephalon Reports Strong First Quarter Earnings
2. Cephalon Appoints Gerald J. Pappert as General Counsel
3. inVentiv Selling Solutions Selected to Provide Sales Team for Cephalon Inc.
4. Cephalon to Present at the 26th Annual JP Morgan Healthcare Conference
5. Cephalon Appoints Valli F. Baldassano as Executive Vice President and Chief Compliance Officer
6. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
7. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
8. United American Healthcare Corporation to Host Fiscal 2008 Third Quarter Results Conference Call May 13th
9. Digirad Corporation to Present at Bank of America 2008 Health Care Conference
10. Zimmer Holdings to Present at Deutsche Bank 33rd Annual Health Care Conference
11. American Pacific to Release Financial Results and Hold Fiscal 2008 Second Quarter Investor Teleconference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/5/2008)...s the Latest Developments in Molecular,Testing and... /PRNewswire-USNewswire/ -- The practice of,pathol...g and the promise,of personalized medicine will ch...and other imaging technologies will change the way...ogists is taking a leadership role in,making sure ...
(Date:9/5/2008)...RNewswire-USNewswire/ -- The Health Resources,and ... million in grants to,increase and improve medical... grants continue President Bush,s historic expansi...w reach more economically,vulnerable and geographi...dministrator Elizabeth M. Duke said. "In 2007, mor...
(Date:9/5/2008)...tical ,anti-cloak, could bring objects out of hidi...-- Just in case someone develops a cloak of invisi... how to uncloak the objects it hides. , Accordi...in materials underneath an invisibility cloak woul...esearchers at Shanghai Jiao Tong University in Chi...
(Date:9/5/2008)...ain to commit to develop a National AIDS,Strategy ...p. 5 /PRNewswire-USNewswire/ -- The,Republican Nat...ion of the,domestic AIDS epidemic in the United St...erseas. Neither Presidential nominee Sen. John McC... mentioned AIDS in their remarks,to Convention del...
Breaking Medicine News(10 mins):Health News:Leaders in Pathology Meet in San Diego: Sept. 25 - 28, 2008 2Health News:HRSA Announces $39 Million in Grants to Expand, Improve Health Center Services 2Health News:Domestic AIDS Epidemic Ignored at Republican National Convention 2Health News:Domestic AIDS Epidemic Ignored at Republican National Convention 3
... the number of foreign-born health care workers in... for transmitting tuberculosis in health-care sett...e experts Timothy R. Sterling, M.D., and David W. ...ed to health care workers with latent TB infection...
...arma company Venus Remedies Ltd today said it has ...or its latest antibiotic fixed dose combination us...w antibiotic combination, active against multi-res...and gram-negative bacteria and provides a broad-sp...
...ny adults who consider suicide fail to seek help f...en those who do ask for help may find it difficult...ording to a new study. "We need to improve access...ideation," said Ruth Klap, Ph.D., a sociologist at...
...e UNICEF has urged that the orphans and vulnerable...al fight against HIV/AIDS.// In their new report... AIDS', Unicef called for renewed vigour to tackle...realize the targets chartered in the UN Millennium...
Other Medicine News:Health News:Many Suicidal Adults Aren't Getting Mental Health Treatment 2
(Date:9/5/2008)...Calif., Sept. 5 /- SARcode,...lecule LFA-1 inhibitors,to treat inflammatory dise...NSS) today announced SARcode,s initiation of a Pha...uct candidate for T-cell mediated ophthalmic,disea...reement providing,SARcode with an exclusive licens...
(Date:9/5/2008)...microRNAs Extracted From a Simple Blood Draw Have,...rkers for a Wide Range of ..., Rosetta Genomics is Currently Developing ... REHOVOT, Israel and JERSEY CITY, New Jersey, Sept..., Ltd. (NASDQ: ROSG), a leader in,the development ...
(Date:9/4/2008)... designation for the treatment of Acute Myeloid ... N.J., Sept. 4 /- Celator Pharmaceuti...inistration (FDA) has granted orphan,drug designat...Injection,for the treatment of Acute Myeloid Leuke...duct two randomized Phase 2,studies with CPX-351. ...
(Date:9/4/2008)...aqMan(R) real-time PCR testing for the diagnostic ... Calif., Sept. 4 /- The U.S. Food & D...BAS(R) TaqMan(R) HBV Test,the first assay for qua...S.,The test uses Roche,s real-time PCR technology ... a patient,s blood. Doctors may use viral load,tes...
Breaking Medicine Technology:SARcode and Sunesis Announce Start of Phase 1 Clinical Trial in Ocular Inflammatory Diseases 2SARcode and Sunesis Announce Start of Phase 1 Clinical Trial in Ocular Inflammatory Diseases 3Rosetta Genomics Identifies Potential microRNA Biomarkers in Blood Serum 2Rosetta Genomics Identifies Potential microRNA Biomarkers in Blood Serum 3Rosetta Genomics Identifies Potential microRNA Biomarkers in Blood Serum 4Celator Pharmaceuticals Receives Orphan Drug Designation for Anticancer Agent CPX-351 2FDA Approves First Hepatitis B Viral Load Test 2FDA Approves First Hepatitis B Viral Load Test 3Study uncovers clues to cystic fibrosis gene dysfunction and gastrointestinal disease 1582 1Study uncovers clues to cystic fibrosis gene dysfunction and gastrointestinal disease 1582 2Cancer research giants collaborate to present the CTRC AACR San Antonio Breast Cancer Symposium 8198 1Cancer research giants collaborate to present the CTRC AACR San Antonio Breast Cancer Symposium 8198 2Cancer research giants collaborate to present the CTRC AACR San Antonio Breast Cancer Symposium 8198 3John Alexandrov Reveals the Secret to Financial Success Via Launch of The Power of Deliberate Creation Audio CDs 8194 1John Alexandrov Reveals the Secret to Financial Success Via Launch of The Power of Deliberate Creation Audio CDs 8194 2John Alexandrov Reveals the Secret to Financial Success Via Launch of The Power of Deliberate Creation Audio CDs 8194 3SmartOps Enterprise Inventory Optimization Software Licensed by Wyeth 8189 1
...ND OAKS, Calif. & COLLEGEVILLE, Pa.--(BUSINESS...th Pharmaceuticals, a,division of Wyeth (NYSE:WYE)...ata that showed that the safety profile of Enbrel(...in patients with,moderate-to-severe juvenile rheum...ars of therapy. JRA is a chronic autoimmune,diseas...
...TON, Mass.--(BUSINESS WIRE)--Jun 13, 2007 - EPIX,P...d that data from,its Phase 3 trial of PRX-00023, a... a poster presentation at the 47th Annual New,Clin...Raton,Florida. The meeting is sponsored by the Na...ty of Clinical Psychopharmacology., The presentati...
Other Medicine Technology:Enbrel Safety Data for up to Eight Years in Patients with Juvenile,Rheumatoid Arthritis Being Presented at EULAR 2Enbrel Safety Data for up to Eight Years in Patients with Juvenile,Rheumatoid Arthritis Being Presented at EULAR 3Enbrel Safety Data for up to Eight Years in Patients with Juvenile,Rheumatoid Arthritis Being Presented at EULAR 4Enbrel Safety Data for up to Eight Years in Patients with Juvenile,Rheumatoid Arthritis Being Presented at EULAR 5Enbrel Safety Data for up to Eight Years in Patients with Juvenile,Rheumatoid Arthritis Being Presented at EULAR 6Enbrel Safety Data for up to Eight Years in Patients with Juvenile,Rheumatoid Arthritis Being Presented at EULAR 7Enbrel Safety Data for up to Eight Years in Patients with Juvenile,Rheumatoid Arthritis Being Presented at EULAR 8EPIX Pharmaceuticals Presents Findings from PRX-00023 Phase 3,Clinical Trial at 47th Annual NCDEU Meeting 2EPIX Pharmaceuticals Presents Findings from PRX-00023 Phase 3,Clinical Trial at 47th Annual NCDEU Meeting 3EPIX Pharmaceuticals Presents Findings from PRX-00023 Phase 3,Clinical Trial at 47th Annual NCDEU Meeting 4
Excellent for manipulation of the intraocular lens in the capsular bag. The angled and curved shaft allows the instrument to reach across the implant and catch the optic/ haptic junction to facilitat
Angled shaft with 1.5 mm tip designed to efficiently perform the "Stop and Chop" technique. Round knurled handle. Most popular size or model.
This double ended instrument was designed for delineating and lifting the corneal flap of previously performed lamellar refractive surgery cases.
Used when dislocating the lens. Great for chopping during phacoemulsification. Helpful in ushering the IOL out of eye. Useful to reduce possibility of iris tuck with anterior chamber IOL placement.
Medicine Products: